Use of infliximab in the treatment of Crohn's disease in children and adolescents

This publication has 21 references indexed in Scilit:

• Endoscopic and histological healing with infliximab anti–tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial
  Gastroenterology, 1999
• Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis
  Published by Elsevier ,1999
• A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease
  New England Journal of Medicine, 1997
• Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)
  Gastroenterology, 1995
• Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions
  Cytokine, 1995
• The Mouse/Human Chimeric Monoclonal Antibody cA2 Neutralizes TNF In Vitro and Protects Transgenic Mice from Cachexia and TNF Lethality In Vivo
  Cytokine, 1995
• Tumor necrosis factor α-producing cells in the intestinal mucosa of children with inflammatory bowel disease
  Gastroenterology, 1994
• Enhand secretion of tumour necrosis factor-alpha, IL-6, and IL-1β by isolated lamina ropria monouclear cells from patients with ulcretive cilitis and Crohn's disease
  Clinical and Experimental Immunology, 1993
• Tumour necrosis factor alpha in stool as a marker of intestinal inflammation
  The Lancet, 1992
• Development and Validation of a Pediatric Crohnʼs Disease Activity Index
  Journal of Pediatric Gastroenterology and Nutrition, 1991